Tandem Diabetes Care Inc. raised $12 million of a $13.7 million funding round spread across eight investors.
Meanwhile, its flagship t:slim insulin pump is under 510(k) review with the FDA as an option for people with Type I diabetes, according to VentureWire.
The current offering, which opened last week, is a mixture of debt and options, according to regulatory filings. The investors were not named.